Download PDF
Ernährung & Medizin 2004; 19(4): 169-177
DOI: 10.1055/s-2004-837279
Vitamin-D-Mangel

© Hippokrates Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Vitamin-D-Mangel als Risikofaktor für Autoimmunerkrankungen, Diabetes mellitus und Herz-Kreislauf-Erkrankungen

Vitamin D deficiency as a risk factor for autoimmune diseases, diabetes, and cardiovascular diseasesWolfgang Bayer, Karlheinz Schmidt
Further Information

Publication History

Publication Date:
04 December 2006 (online)

    Permissions and Reprints

Zusammenfassung

Vitamin D kann oral aufgenommen oder endogen in der Haut unter dem Einfluss von UV-Strahlung gebildet werden. In der Leber folgt eine Hydroxylierung zum 25-Hydroxy-Vitamin D3 und in der Niere eine weitere Hydroxylierung zu 1,25-Dihydroxy-Vitamin D3 (Calcitriol), einem wichtigen Steroidhormon. Calcitriol ist der aktivste Vitamin-D-Metabolit im Calciumstoffwechsel. Auch verschiedene andere Gewebe können Calcitriol bilden und einen Vitamin-D-Rezeptor exprimieren; dies weist auf eine physiologische Rolle von Vitamin D hin, die über den Calciumstoffwechsel und die Knochenbildung hinausgeht. Epidemiologische Daten zeigen einen niedrigen Vitamin-D-Status bzw. -Mangel bei Patienten mit Autoimmunerkrankungen wie Multipler Sklerose, rheumatoider Arthritis und entzündlichen Darmerkrankungen sowie bei Diabetikern und bei Patienten mit Herzinsuffizienz und Hypertonie. Die Gabe von Vitamin D kann günstige Wirkungen bei diesen Erkrankungen haben.

Die aktuellen Zufuhrempfehlungen der Deutschen Gesellschaft für Ernährung bezüglich Vitamin D betragen 5 μg für den erwachsenen Menschen (10 μg für Patienten über 65 Jahre). Diese Zufuhr ist in der Regel nicht ausreichend, um optimale Serumkonzentrationen von Vitamin D einzustellen. Eine ungenügende Vitamin-D-Versorgung kann mit verschiedenen chronischen Erkrankungen des älteren Menschen korrelieren wie Autoimmunerkrankungen, Diabetes, Hypertonie, Herzinsuffizienz und verschiedenen Tumoren.

Summary

Vitamin D formed in the skin after exposure to UV-light or orally ingested is metabolized in the liver to 25-hydroxy-vitamin D3 and further more in the kidney to 1,25-dihydroxy-vitamin D3, calcitriol, an important steroid hormone. Also different other tissues are capable of producing calcitriol or possess a vitamin-D-receptor and this indicates a physiological role of vitamin D exceeding the regulation of calcium metabolism and bone formation. Epidemiological data indicate an insufficient vitamin D status in patients with autoimmune disorders such as multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease, in diabetic patients and in patients with congestive heart failure and hypertension. Vitamin D supplementation may have beneficial effects in these disorders and can e.g. suppress the induction of autoimmune encephalomyelitis, an animal model of MS and has been shown to improve clinical symptoms in patients with rheumatoid arthritis. In type 1 diabetes it can influence the autoimmune process and in type 2 diabetes it can improve insulin resistance. Reduction of blood pressure was also shown under vitamin D supplementation in normotensive as well as hypertensive patients and patients with congestive heart failure often exhibit vitamin D deficiency.

The recommended dietary allowance for vitamin D for adults in Germany is 5 μg (10 μg for elderly people) but this dose may be insufficient to achieve optimal serum concentrations of vitamin D and vitamin D deficiency may be associated with different chronic disorders of elderly people such as autoimmune disorders, diabetes, hypertension, congestive heart failures, and some types of cancer.

Schlüsselwörter

Vitamin D - Steroidhormon - Autoimmunerkrankungen - Diabetes - Hypertonie - Herzinsuffizienz - Zufuhrempfehlungen

Key words

Vitamin D - steroid hormone - autoimmune disorders - diabetes - hypertension - congestive heart failure - recommended dietary allowances

Literatur

  • 1 Aguado P. et al. . Low vitamin D levels in outpatient post-menopausal women from a rheumatology clinic in Madrid, Spain: their relationship with bone mineral density.  Osteoporos Int. 2000;  11 739-744
    CrossrefPubMedGoogle Scholar
  • 2 Aksoy H. et al. . Serum 1,25-dihydroxy-vitamin D (1,25(OH)2D3), 25-hydroxy-vitamin D (25(OH)D3) and parathormone levels in diabetic retinopathy.  Clin Biochem. 2000;  33 47-51
    CrossrefPubMedGoogle Scholar
  • 3 Andjelkovic Z. et al. . Disease modifying and immunomodulatory effects of high dose 1-alpha-(OH)-D3 in rheumatoid arthritis patients.  Clin Exp Rheumatol. 1999;  17 453-456
    PubMedGoogle Scholar
  • 4 Barger-Lux MJ. et al. . An investigation of sources of variation in calcium absorption efficiency.  J Clin Endocrinol Metab. 1995;  80 406-411
    CrossrefPubMedGoogle Scholar
  • 5 Bayer W. Endemischer Vitamin-D-Mangel in Mitteleuropa?.  [Editorial] Ernährung & Medizin. 2004;  19 55
    PubMedGoogle Scholar
  • 6 Bayer W, Schmidt K. Besteht in Mitteleuropa ein endemischer Vitamin-D-Mangel?.  Erfahrungsheilkunde. 2004;  53 609-613
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Baynes KC. et al. . Vitamin D, glucose tolerance and insulinaemia in elderly men.  Diabetologia. 1997;  40 344-347
    CrossrefPubMedGoogle Scholar
  • 8 Borissova AM. et al. . The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients.  Int J Clin Pract. 2003;  57 258-261
    PubMedGoogle Scholar
  • 9 Bucher HC. et al. . Effect of calcium supplementation on blood pressure: a meta-analysis of randomized controlled trials.  JAMA. 1996;  275 1016-1022
    CrossrefPubMedGoogle Scholar
  • 10 Burgess ED. et al. . Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension.  Am J Hypertens. 1990;  3 903-905
    PubMedGoogle Scholar
  • 11 Cantorna MT. Vitamin D and autoimmunity: Is vitamin D status an environmental factor affecting autoimmune disease prevalence?.  Proc Soc Exp Biol Med. 2000;  223 230-233
    CrossrefPubMedGoogle Scholar
  • 12 Cantorna MT, Hayes CE, DeLuca HF. 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis.  Proc Natl Acad Sci USA. 1996;  93 7861-7864
    CrossrefPubMedGoogle Scholar
  • 13 Cantorna MT, Humpal-Winter J, DeLuca HF. In vivo upregulation of interleukin-4 is one mechanism underlying the immunoregulatory effects of 1,25-dihydroxyvitamin D3.  Arch Biochem Biophys. 2000;  377 135-138
    CrossrefPubMedGoogle Scholar
  • 14 Cantorna MT, Munsick C. et al. . 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease.  J Nutr. 2000;  130 2648-2652
    PubMedGoogle Scholar
  • 15 Cosman F. et al. . Fracture history and bone loss in patients with MS.  Neurology. 1998;  51 1161-1165
    CrossrefPubMedGoogle Scholar
  • 16 DeLuca HF, Cantorna MT. Vitamin D: Its role and uses in immunology.  FASEB J. 2001;  15 2579-2585
    CrossrefPubMedGoogle Scholar
  • 17 Fukazawa T. et al. . Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese.  J Neurol Sci. 1999;  166 47-52
    CrossrefPubMedGoogle Scholar
  • 18 Goertz B. et al. . Vitamin D receptor genotypes are not associated with rheumatoid arthritis or biochemical parameters of bone turnover in German RA patients.  Clin Exp Rheumatol. 2003;  21 333-339
    PubMedGoogle Scholar
  • 19 Harries AD. et al. . Vitamin D status in Crohn's disease: association with nutrition and disease activity.  Gut. 1985;  26 1197-1203
    PubMedGoogle Scholar
  • 20 Hayes CE. et al. . The immunological functions of the vitamin D endocrine system.  Cell Mol Biol (Noisy-le-grand). 2003;  49 277-300
    PubMedGoogle Scholar
  • 21 Hein G, Oelzner P. Vitamin D metabolites in rheumatoid arthritis: findings - hypotheses - consequences.  Z Rheumatol. 2000;  59 28-32
    CrossrefPubMedGoogle Scholar
  • 22 Hyppönen E. et al. . Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study.  Lancet. 2001;  358 1500-1503
    CrossrefPubMedGoogle Scholar
  • 23 Isaia G. et al. . High prevalence of hypovitaminosis D in female type 2 diabetic population.  Diabetes Care. 2001;  24 1496
    CrossrefPubMedGoogle Scholar
  • 24 Jahnsen J. et al. . Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease.  Scand J Gastroenterol. 2002;  37 192-199
    CrossrefPubMedGoogle Scholar
  • 25 Jespersen B. et al. . Acute cardiovascular effect of 1,25-dihydroxycholecalciferol in essential hypertension.  Am J Hypertens. 1998;  11 659-666
    CrossrefPubMedGoogle Scholar
  • 26 Kimura. et al. . Effectiveness of 1,25-dihydroxyvitamin D3 supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity.  Intern Med. 1999;  38 31-35
    PubMedGoogle Scholar
  • 27 Krause R. et al. . Ultraviolet B and blood pressure.  Lancet. 1998;  352 709-710
    PubMedGoogle Scholar
  • 28 Kristal-Boneh E, Froom P. et al. . Association of calcitriol and blood pressure in normotensive men.  Hypertension. 1997;  30 1289-94
    PubMedGoogle Scholar
  • 29 Krüger C. et al. . Intracellular calcium handling in isolated ventricular myocytes from cardiomyopathic hamsters (strain BIO 14.6) with congestive heart failure.  Cell Calcium. 1994;  16 500-508
    CrossrefPubMedGoogle Scholar
  • 30 Lange U. et al. . Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis.  Osteoporos Int. 2001;  12 1031-1035
    CrossrefPubMedGoogle Scholar
  • 31 Lemire JM, Adams JS. 1,25-dihydroxyvitamin D3 inhibits the passive transfer of cellular immunity by a myelin basic protein-specific T-cell clone.  J Bone Miner Res. 1992;  7 171-177
    PubMedGoogle Scholar
  • 32 Li YC, Kong J, Wei M. et al. . 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system.  J Clin Invest. 2002;  110 229-238
    CrossrefPubMedGoogle Scholar
  • 33 Li YC, Qiao G. et al. . Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure.  J Steroid Biochem Mol Biol. 2004;  89-90 387-392
    CrossrefPubMedGoogle Scholar
  • 34 Lind L, Hanni A, Lithell H. et al. . Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men.  Am J Hypertens. 1995;  8 894-901
    CrossrefPubMedGoogle Scholar
  • 35 Lind L, Lithell H. et al. . Reduction of blood pressure by treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance.  Acta Med Scand. 1988;  223 211-217
    PubMedGoogle Scholar
  • 36 Lind L, Wengle B, Wide L. et al. . Hypertension in primary hyperparathyroidism - reduction of blood pressure by long-term treatment with vitamin D (alphacalcidol). A double-blind, placebo-controlled study.  Am J Hypertens. 1988;  1 397-402
    PubMedGoogle Scholar
  • 37 Lind L, Wengle B, Wide L. et al. . Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study.  Am J Hypertens. 1989;  2 20-25
    PubMedGoogle Scholar
  • 38 Mahon BD, Gordon SA. et al. . The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells.  J Cell Biochem. 2003;  89 922-932
    CrossrefPubMedGoogle Scholar
  • 39 Mahon BD, Wittke A. et al. . Cytokine profile in patients with multiple sclerosis following vitamin D supplementation.  J Neuroimmunol. 2003;  134 128-132
    CrossrefPubMedGoogle Scholar
  • 40 Meehan MA. et al. . 1,25-Dihydroxyvitamin D3 enhances generation of non-specific suppressor cells while inhibiting the induction of cytotoxic cells in a human MLR.  Cell Immunol. 1992;  140 400-409
    CrossrefPubMedGoogle Scholar
  • 41 Meehan TF, DeLuca HF. CD8+ T cells are not necessary for 1,25-dihydroxyvitamin D3 to suppress experimental autoimmune encephalomyelitis in mice.  Proc Natl Acad Sci USA. 2002;  99 5557-5560
    PubMedGoogle Scholar
  • 42 Merlino LA. et al. . Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study.  Arthritis Rheum. 2004;  50 72-77
    CrossrefPubMedGoogle Scholar
  • 43 Motohashi Y. et al. . Vitamin D receptor gene polymorphism affects onset pattern of type 1 diabetes.  J Clin Endocrinol Metab. 2003;  88 3137-3140
    CrossrefPubMedGoogle Scholar
  • 44 Munger KL. et al. . Vitamin D intake and incidence of multiple sclerosis.  Neurology. 2004;  62 60-65
    CrossrefPubMedGoogle Scholar
  • 45 Nakamura H. et al. . High serum and synovial fluid granulocyte colony stimulating factor (G-CSF) concentrations in patients with rheumatoid arthritis.  Clin Exp Rheumatol. 2000;  18 713-718
    PubMedGoogle Scholar
  • 46 Nieves J. et al. . High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis.  Neurology. 1994;  44 1687-92
    CrossrefPubMedGoogle Scholar
  • 47 Nishio K. et al. . Congestive heart failure is associated with the rate of bone loss.  J Intern Med. 2003;  253 439-446
    CrossrefPubMedGoogle Scholar
  • 48 Oelzner P.. et al. . Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis.  Calcif Tissue Int. 1998;  62 193-198
    CrossrefPubMedGoogle Scholar
  • 49 Oh JY, Barrett-Connor E. Association between vitamin D receptor polymorphism and type 2 diabetes or metabolic syndrome in community-dwelling older adults: the Rancho Bernardo Study.  Metabolism. 2002;  51 356-359
    CrossrefPubMedGoogle Scholar
  • 50 Ortlepp JR. et al. . The vitamin D receptor gene variant is associated with the prevalence of type 2 diabetes mellitus and coronary artery disease.  Diabet Med. 2001;  18 842-845
    CrossrefPubMedGoogle Scholar
  • 51 Pfeifer M. et al. . Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women.  J Clin Endocrinol Metab. 2001;  86 1633-1637
    CrossrefPubMedGoogle Scholar
  • 52 Rostand SG. Ultraviolet light may contribute to geopraphic and racial blood pressure differences.  Hypertension. 1997;  30 150-156
    CrossrefPubMedGoogle Scholar
  • 53 Shane E. et al. . Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure.  Am J Med. 1997;  103 197-207
    PubMedGoogle Scholar
  • 54 Siffledeen JS. et al. . The frequency of vitamin D deficiency in adults with Crohn's disease.  Can J Gastroenterol. 2003;  17 473-478
    PubMedGoogle Scholar
  • 55 Sigmund CD. Regulation of renin expression and blood pressure by vitamin D3.  J Clin Invest. 2002;  110 155-156
    CrossrefPubMedGoogle Scholar
  • 56 Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease.  J Intern Med. 1996;  239 131-137
    CrossrefPubMedGoogle Scholar
  • 57 Simmons JD. et al. . Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility.  Gut. 2000;  47 211-214
    CrossrefPubMedGoogle Scholar
  • 58 Simpson RU, Weishaar RE. Involvement of 1,25-dihydroxyvitamin D3 in regulating myocardial calcium metabolism: physiological and pathological actions.  Cell Calcium. 1988;  9 285-292
    CrossrefPubMedGoogle Scholar
  • 59 Skrabic V. et al. . Vitamin D receptor polymorphism and susceptibility to type 1 diabetes in the Dalmatian population.  Diabetes Res Clin Pract. 2003;  59 31-35
    CrossrefPubMedGoogle Scholar
  • 60 Stio M. et al. . Suppressive effect of 1,25-dihydroxyvitamin D3 and its analogues EB 1089 and KH 1060 on T lymphocyte proliferation in active ulcerative colitis.  Biochem Pharmacol. 2001;  61 365-371
    CrossrefPubMedGoogle Scholar
  • 61 Takeuchi A. et al. . Nuclear factor of activated T cells (NFAT) as a molecular target for 1,25-dihydroxyvitamin D3-mediated effects.  J Immunol. 1998;  160 209-218
    PubMedGoogle Scholar
  • 62 Tsuda K. et al. . Bone mineral density in women with essential hypertension.  Am J Hypertens. 2001;  14 704-707
    CrossrefPubMedGoogle Scholar
  • 63 van Amerongen BM, Dijkstra CD. et al. . Multiple sclerosis and vitamin D: an update.  Eur J Clin Nutr. 2004;  58 1095-1109
    CrossrefPubMedGoogle Scholar
  • 64 van Etten E, Decallonne B, Mathieu C. 1,25-dihydroxycholecalciferol: endocrinology meets the immune system.  Proc Nutr Soc. 2002;  61 375-380
    CrossrefPubMedGoogle Scholar
  • 65 von Tirpitz C, Steder-Neukamm U. et al. . Osteoporosis in inflammatory bowel disease - results of a survey among members of the German Crohn's and Ulcerative Colitis Association.  Z Gastroenterol. 2003;  41 1145-50
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 Watson KE. et al. . Active serum vitamin D levels are inversely correlated with coronary calcification.  Circulation. 1997;  96 1755-60
    CrossrefPubMedGoogle Scholar
  • 67 Wortsman J. et al. . Decreased bioavailability of vitamin D in obesity.  Am J Clin Nutr. 2000;  72 690-693
    PubMedGoogle Scholar
  • 68 Young EW. et al. . Regulation of parathyroid hormone and vitamin D in essential hypertension.  Am J Hypertens. 1995;  8 957-964
    CrossrefPubMedGoogle Scholar
  • 69 Zella JB. et al. . Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus.  Arch Biochem Biophys. 2003;  417 77-80
    PubMedGoogle Scholar
  • 70 Zittermann A. et al. . Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?.  J Am Coll Cardiol. 2003;  41 105-112
    PubMedGoogle Scholar

Dr. rer. nat. Wolfgang Bayer
Prof. Dr. Dr. med. Karlheinz Schmidt

Laboratorium für spektralanalytische und biologische Untersuchungen

Dr. Bayer GmbH

Bopserwaldstr. 26

70184 Stuttgart

      >